Inflammation Decreases Ciclosporin Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Archive ouverte

Malnoë, David | Bories, Mathilde | Pierre-Jean, Morgane | Marchand, Tony | Le Corre, Pascal

Edité par CCSD ; Wiley -

International audience. Graft-versus-host disease (GVHd) remains a significant challenge following allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of GVHd relies mainly on the use of calcineurin inhibitors, notably ciclosporin that exhibits complex pharmacokinetics influenced by many factors including drug-drug interactions (DDIs). Due to the downregulation of drug metabolizing enzymes and transporters, it has been postulated that inflammation may be a contributing factor to the variability observed in ciclosporin pharmacokinetics. This study aimed to assess the impact of inflammation, as indicated by C-reactive protein (CRP) levels, on the metabolism of ciclosporin in adult allogeneic HSCT recipients. A retrospective observational study was conducted at Rennes University Hospital involving 71 adult HSCT patients. The relationship between the intensity of inflammation (no-to-mild, moderate, and severe), and the metabolism of ciclosporin (estimated by the concentration/dose ratio) was assessed. Severe inflammation significantly decreased the metabolism of ciclosporin, as evidenced by higher concentration/dose ratios. Thanks to the daily dose adjustment, inflammation did not influence the blood levels of ciclosporin. Interestingly, DDIs did not emerge as a significant covariate in influencing ciclosporin metabolism. This is likely because the CYP3A4 inhibitory potential of interacting drugs may be masked in HSCT patients where metabolism is already upstream downregulated by inflammation. The study highlights the intricate relationship between inflammation and ciclosporin pharmacokinetics in HSCT patients. This underscores the necessity for therapeutic monitoring and the potential adjustment of dosage strategies based on the inflammatory status. These insights could contribute to the development of more personalized, optimized, and effective management strategies for HSCT recipients.

Suggestions

Du même auteur

Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients

Archive ouverte | Malnoë, David | CCSD

International audience. Objectives: Letermovir, a cytomegalovirus prophylactic agent, is widely used in allogeneic HSCT recipients. As an inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), it may i...

Leveraging Clinical Data Warehouses to Measure Impact of Update Prescription Guidelines of Polyvalent Immunoglobulins in 2018 in France

Archive ouverte | Pierre-Jean, Morgane | CCSD

International audience. In France and in other countries, we observed a significant growth in human polyvalent immunoglobulins (PvIg) usage. PvIg is manufactured from plasma collected from numeral donors, and its pr...

Measurement of Cumulative Drug Exposure from Clinical Data Warehouse

Archive ouverte | Bories, Mathilde | CCSD

International audience. Polypharmacy (PP) and hyperpolypharmacy (HPP), are prevalent among cancer patients and are associated with an increased risk of drug-drug interactions (DDI) and potentially inappropriate medi...

Chargement des enrichissements...